Related Experiment Video

Updated: Jun 15, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Clinical trials on systemic necrotizing vasculitides

Loïc Guillevin1

  • 1Service de médecine interne, hôpital Cochin, Assistance publique-Hôpitaux de Paris, université Paris-René-Descartes, rue du Faubourg-Saint-Jacques, Paris cedex 14, France. loic.guillevin@cch.aphp.fr

Presse Medicale (Paris, France : 1983)
|March 9, 2010
PubMed

Insights

Treatments for systemic necrotizing vasculitides have advanced, with clinical trials optimizing conventional drugs and exploring new immunomodulating therapies like biotherapies for better outcomes.

Area of Science:

  • Rheumatology and Immunology
  • Internal Medicine

Background:

  • Systemic necrotizing vasculitides require evolving treatment strategies.
  • Conventional therapies aim to improve survival and reduce side effects.

Purpose of the Study:

  • To review the progression of treatment strategies for systemic necrotizing vasculitides.
  • To highlight the role of clinical trials in optimizing therapies.

Main Methods:

  • Evaluation of conventional drug indications and their impact on survival and relapses.
  • Inclusion of immunomodulating methods such as plasma exchange and intravenous immunoglobulins.
  • Assessment of novel biotherapies, including anti-tumor necrosis factor-alpha and anti-CD20 monoclonal antibodies.

Main Results:

  • Prospective clinical trials, notably by the French and European Vasculitis Study Groups, have refined targeted treatments.
  • Immunomodulating agents and biotherapies show promise in managing these conditions.
  • Ongoing trials are evaluating the efficacy of new therapeutic agents.

Conclusions:

  • Treatment for systemic necrotizing vasculitides has significantly progressed.
  • Biotherapies represent a promising frontier in managing vasculitis, with ongoing research to confirm their benefits.

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Cytotoxic Edema: Pathophysiology01:21

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...